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Abstract
The novel properties of nanoparticulate materials (NPM) and the rapid development of NPM based
products have raised many unanswered questions and concerns by diﬀerent stakeholders over its conse-
quences for the environment and human health. These concerns have led to an increasing discussion in both
the US and Europe about possible regulatory policies for NPM. In this article a comparative study of
stakeholders perceptions on regulatory policy issues with NPM in Europe is presented. It was found that
industry wants to regulate this area if the scientiﬁc evidence demonstrates that NPM are harmful, but also
that the regulatory bodies do not ﬁnd it necessary at this point of time to regulate until scientiﬁc evidence
demonstrates that NPM are harmful. This research therefore shows that there will most likely not be any
regulatory interventions until there is an established and convincing scientiﬁc knowledge base demon-
strating that NPM can be hazardous. It is furthermore discussed in this article the diﬀerent roles and
responsibilities of the stakeholders in ﬁnancing the research required to establish the necessary level of
fundamental scientiﬁc evidence. It was also found that the activity of the regulatory bodies on this issue
diﬀer between the European countries.
Introduction
The novel properties of nanoparticulate materials
(NPM) are researched widely for many diﬀerent
applications ranging from light-weight materials,
drug-delivery systems to renewable energy.
Expectations are huge: nanotechnology is believed
to change the way everything is made and designed
in society (NSTC, 1999). However, the novel
properties of NPM and the rapid development of
NPM based products have also raised many
unanswered questions and concerns over its con-
sequences for the environment and human health.
In short: do we have reasons to worry about
NPM?
Nanoparticles are often deﬁned as particles less
than 100 nm in diameter (The Royal Society &
The Royal Academy of Engineering, 2004) and
can be divided into three main categories (Helland,
2004): (i) particles that are produced unintention-
ally (e.g., diesel engines and welding processes) or
originate from natural sources (volcanoes and
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forest ﬁre); (ii) particles produced in bulk in tra-
ditional industries such as the chemical industry or
the polymer industry (e.g., carbon black and tita-
nium dioxide); (iii) particles that are deliberately
engineered to have speciﬁc properties and charac-
teristics only existing in the nano-range and
utilized for a speciﬁc function (e.g., carbon
nanotubes, fullerenes and quantum dots); In this
article, the term ,nanoparticulate materials repre-
sents the two latter categories as engineered
materials that are less than 100 nm in at least two
dimensions.
The scientiﬁc literature available of potential
hazards of NPM indicates that NPM may be
harmful, although the scientiﬁc knowledge base is
minimal in these areas (Warheit, 2004). The
exposure to ambient air particles and their inﬂu-
ence on health is well documented through epide-
miological studies. These epidemiological studies
suggest that an increase in ambient particle con-
centration is related to an increase in acute mor-
bidity and mortality (von Klot et al., 2005).
Studies indicate that the decrease of particle size
and the corresponding increase in relative surface
area correlates with an increase in defense reaction
in the lung tissue (Oberdorster, 2001; Donaldson,
et al., 2002; Zhang et al., 2003; Donaldson et al.,
2004a) and the inhalation of nanoparticles may
cause diseases like lung cancer, ﬁbrosis and
inﬂammation in the lung and further worsen car-
diovascular or respiratory diseases like asthma or
bronchitis (Borm, 2004; Donaldson, 2004b; Stone,
2004). However, it is important to note that this
lung toxicity database has been limited to studies
of three types of nanoparticles: titanium dioxide,
carbon black and diesel particles (Warheit, 2004).
NPM may also translocate within the body, for
example from the nose and lungs to the central
nerve system, the brain, into the systemic circula-
tion and to organs like the liver (Nemmar et al.,
2001; Takenaka et al., 2001; Kreyling et al., 2002;
Oberdorster et al., 2002; 2004; Takenaka et al.,
2004). The research covering the new types of
NPM is limited and the number of studies of the
environmental impacts of NPM are few. Carbon
nanotubes have been shown to cause granulomas
in the lungs of animals, an immunological
response to foreign objects (Lam et al., 2004;
Warheit et al., 2004; Muller et al., 2005; Shvedova
et al., 2005), and was found in one study to be
more toxic than carbon black and quartz (Lam
et al., 2004). Fullerenes have been shown in studies
to be bioavailable when released in aqueous envi-
ronments, cause lipid peroxidation in ﬁshbrain
(Oberdorster, 2004a) and inhibit bacterial growth
(Fortner et al., 2005). Rendering the surface
chemistry or coating may provide an attractive
strategy in reducing toxicity. A recent study has
shown that increasing the degree of sidewall
functionalization decreases the cytotoxicity of
single-walled carbon nanotubes (Sayes et al.,
2006). However, this may be diﬃcult in some
environmental settings or the body. For example,
UV-light or enzymes may modify the safety coat-
ings by turning coated fullerenes into more toxic
uncoated fullerenes (E. Oberdorster, 2004b). Two
other factors that determine the potential impacts
of NPM on environmental and human health are
the level of biopersistency and biodegradability
(Borm & Kreyling, 2004). The concerns regarding
the toxic potential of NPM have lead to the
announcement of a new sub-discipline called
nanotoxicology, which has been deﬁned as safety
evaluation of engineered nanostructures and nan-
odevices (Oberdo¨rster et al., 2005).
Based on the concerns raised and the limited
regulations for producers on how to deal with their
products, there is an increasing debate in the US
and Europe on regulatory issues, NPM handling
procedures and labeling of nanobased products
(Haum et al., 2004; Roco, 2005). For example, the
reinsurance company Swiss Re sees one of the
biggest challenge for regulations is to develop
standardizations of nanomaterials and substances
and a universal nomenclature (Hett, 2004). A
report from the Royal Society in the UK ﬁnds it
likely that several regulatory bodies will have to
look deeper into the issue and express that they
strongly believe that ﬂexible and proportionate
regulatory measures informed by scientiﬁc evi-
dence are beneﬁcial to everybody; the public,
consumers and employees are protected from
harm while industry is able to participate in
developing standards and preparing guidance
to ensure a level playing ﬁeld and reduced risk
of liability.
(The Royal Society & The Royal Academy of
Engineering, 2004).
The European Commission (EC) action plan for
2005–2009 states that because the presence of
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nanobased products in the market is expected to
increase rapidly, particular attention should be
paid to market ready products and risk assess-
ments should be done ex ante commercialization
due to the potential impacts of nanoparticles on
human health and the environment (EC, 2005a).
The EC states further in the action plan that it will
examine and, if needed, propose adaptations of
European Union regulations, develop risk assess-
ments for nanoproducts integrating all stages of
the life cycle of the technology, promote measures
for minimizing exposure of workers, consumers
and the environment, and identify and address
safety concerns with applications and use of
nanoscience and nanotechnology at the earliest
possible stage.
Limited research eﬀorts have been focused on
the perceptions of the diﬀerent stakeholders of
NPM regulations. However, Haum et al. (2004)
oﬀered a preliminary ﬁnding from their survey.
Nanotechnology is only in rare cases a part of the
regulatory bodys agenda and argued that their
ﬁndings demonstrated that ,the regulators in dif-
ferent member states in the European Region have
taken no action at all. How the diﬀerent actors
perceive the issue is important for establishing a
successful scheme that supports the beneﬁcial
innovations, but at the same time protects human
health and environment. Therefore, the purpose of
this research was to investigate stakeholders per-
ceptions of NPM regulations, with a closer focus
on occupational health settings since exposure to
humans in occupational settings will take place ﬁrst
and thus potential eﬀects are expected there ﬁrst.
This study is a comparative assessment of the
perceptions of diﬀerent stakeholders on regulatory
policy issues in Europe.
Methodology
The information in this study was collected
through structured phone interviews with experts
from academia, an outspoken non-governmental
organisation (NGO), representatives from occu-
pational health and safety agencies, a representa-
tive from the EC and NPM producer
representatives with expertise in occupational
health and safety and environmental issues. There
were in total 21 interviews conducted.
We found it necessary to have an interdic-
iplinary pool of experts from academia. As such
we composed a list of 20 scientists with expertise of
NPM regarding environmental impacts such as
ecotoxicology, and health impacts such as occu-
pational health, cell toxicity, lung toxicity and
biological aspects. They were located from a lit-
erature review as key authors, participation lists of
conferences and workshops in the ﬁeld and sug-
gestions from other people working in the ﬁeld.
They are considered as leading scientists in Europe
and the USA. From this pool in-depth, structured
interviews were conducted by phone with nine
scientists from Europe and, as we found few
European scientists with expertise in environmen-
tal issues, we also interviewed one scientist from
the USA.
There are a limited number of NGOs active in
the nanotechnology debate in Europe. The two
media-dominant NGOs, with a position on
nanotechnology, Greenpeace in the UK and the
ETC-groups European representative, were asked
to participate, but only the ETC-group chose to.
The interview method and questions were the same
as for the scientists.
The representatives from the occupational
health and safety agencies in Germany, Switzer-
land and the UK and the representative from the
EC were chosen by the organizations themselves in
response to a direct request to their main oﬃces
for an interview about risks of NPM. The opin-
ions, conclusions and recommendations expressed
were those of the representatives and do not nec-
essarily represent the opinion of their organiza-
tions. The interviews were conducted by phone
and consisted of structured questions that were
more detailed on occupational health regulatory
issues than for scientists and NGO.
The NPM producers were interviewed by phone
and/or through written surveys with the same
questions for both interviewing methods, which
were more detailed on industrial regulatory issues.
The companies were selected based on literature
reviews of NPM producers, participation-lists in
workshops and conferences and from suggestions
of experts and others working in the ﬁeld of NPM
research and development. From these diﬀerent
sources, the most prominent producers in terms of
research or quantity of NPM produced were asked
to participate. There were in total 13 producers
that were approached and six of those chose to
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participate. The companies wished to be anony-
mous and are thus not identiﬁed here. In general,
there were two categories of companies partici-
pating, large multinational chemical companies,
hereby called established companies, and rela-
tively recently founded companies, hereby named
,young companies. The established companies
have several products in their portfolio and more
resources than the young companies. The NPM
produced by the established companies can typi-
cally be produced in several tons per year and
include for example established NPM such as
carbon black. The young companies have typically
developed new NPM as for example carbon na-
notubes. The production methods typically origi-
nate from a university research lab and the
production volume is still small. There are three
companies representing each category.
To uncover the perceptions of these stakehold-
ers, in-depth structured interviews were conducted.
The interviews were then transcribed and the
stakeholders were given the opportunity to clarify
their statements based on the transcript. The
answers were then analyzed with the perceptions
of the following regulatory issues as common
nominators: need of regulations, point of time,
type of regulations and which NPM should be
regulated. The diﬀerent stakeholders were then
compared and the implications discussed.
Stakeholder perceptions of NPM regulatory policy
Identifying the perceptions of stakeholders is
important for understanding the stakeholders
potential impact on projects and processes. In
turn, this contributes to the formulation of
appropriate strategies that maximizes a stake-
holders positive inﬂuence and minimizes any
negative inﬂuence (Bourne & Walker, 2005). The
development of NPM, as any emerging technol-
ogy, is characterized with high uncertainty and
ambiguity. The important stakeholders in the
NPM sphere, such as scientists, NGOs, and
industry, will strongly inﬂuence the debate on
regulatory policy issues and thus, how regulatory
schemes will function and be implemented. Whe-
ther a regulatory scheme for NPM is needed or
how successfully it can be implemented will be
largely inﬂuenced by these stakeholders as well as
the regulatory bodies themselves. In a UK survey
studying the general publics awareness of nano-
technology, only 19% of the survey sample could
oﬀer any form of deﬁnition of nanotechnology
(The Royal Society & The Royal Academy of
Engineering, 2004). Due to this low public
awareness, we did not include the public or the
labor as stakeholders for our study. We therefore
investigated the perceptions of the following
stakeholders scientists, NGOs, regulatory bodies
and industry in order to see where there are con-
sensus points, as well as opposing opinions. The
following sections summarize the stakeholder
opinions as given in the interviews.
Scientists about regulations
Today materials are generally regulated by unit of
mass, but this approach is problematic for NPM,
as it does not take their speciﬁc properties into
account. Therefore, it is important to ﬁnd out
which measurement unit(s) regulations should
address including the unique properties of NPM.
The authorities should initiate exposure assess-
ment and proper toxicological research to ﬁnd out
how severe these risks may be. However in the ﬁeld
of air pollution, there are already enough ratio-
nale, based on scientiﬁc evidence, to regulate NPM
originating from the combustion process. The
exposure assessments and toxicological research
initiated by the authorities should be comple-
mented by implementing toxicology and screening
tests for producers, to ensure that producers do
proper risk assessments before launching the
products. If authorities are working together with
industry and the scientiﬁc community, precau-
tionary measures can be taken which are based on
epidemiological and toxicological studies. How-
ever, history has shown that it takes too long
between when scientists say there might be a
problem and until something actually happens
from the authorities side. Therefore, authorities
could bypass the normal way of asking for scien-
tiﬁc evidence and immediately start thinking about
what may need to be done in order to have pre-
dictable ways of dealing with the problem if it
turns out to be necessary. This might involve
organizing the regulatory process diﬀerently, such
as calling for workshops early in the process.
Informing the producers about risks associated
with their products could be another task of the
authorities and at this stage issuing precautionary
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guidelines instead of regulations could be an
important tool of prevention.
NGO about regulations
The ETC-group ﬁnds that NPM need to be indi-
vidually treated in regulatory settings and believes
that an approach similar to the new EU chemical
regulation, REACH1 (EC, 2003), could be
appropriate for NPM. With this type of regula-
tion, producers have to prove their products safe
through providing a risk assessment to sell their
products on the European market. However,
before that can happen, a standardised model on
how to do toxicological tests methods for NPM
needs to be agreed to by scientists. These tests
should be done by independent assessment bodies.
Furthermore, the ETC-group wants agreed pro-
tocols on how NPM is handled in laboratories or
production sites. In turn, this might make ETC-
groups current call for a moratorium obsolete.
European Commission about regulations
There is today no exposure data available in the
European Union. What exists are hazards identi-
ﬁed for NPM derived through lab experiments or
theoretical considerations. In response to the raised
considerations, the EC has convened expert groups
and are performing workshops to discuss the issue.
Additionally in the Towards a European Strategy
for Nanotechnology communication, which is a
non-binding policy declaration, there are also
actions identiﬁed (EC, 2004). In the light of history,
the representative believes it is quite unique that the
EC is considering risks from the start of an EC-
promotion of a technology. The representative also
believes that the EC as an institution cannot move
much faster than it has done.
Criticism has been raised against the National
Nanotechnology Initiative in the US, questioning
that some of the environmental budget is being
used to research remediation solutions of existing
problems, without seriously researching whether
the technology itself has environmental impacts
(Service, 2004). The representative admits that also
within the EU applications for ﬁxing existing
problems may be promoted, even though testing
whether they are inherently safe for the environ-
ment or human health has not occurred. However,
through the declarations and statements that the
EC has made, the representative believes that the
EC sees the need to do nano-toxicological and
ecotoxicological research and for redoing the
toxicology that is done for bulk substances for
nanoparticulate substances.
At this stage in the development, EC is cautious,
but not pre-cautious in the sense of invoking the
precautionary principle as declared in the com-
munication from the commission on the precau-
tionary principle (EC, 2000). However, the EC is
precautious in the way that it tries to ﬁnance
research projects that include elements of risk
awareness and risk analysis and the EC commu-
nications on nanotechnology have a strong com-
ponent of safety, and it seems likely that it will be
followed up by the action plan. The health and
safety policies are national competences and the
EC should not trespass the limits of EC compe-
tences and thus will leave it to the member states to
handle those issues. However, the EC tries to
inform and raise awareness on this issue among
the member states as well as industry.
The EC is not ahead of the market. There is an
existing situation with market available products
and the EC needs to have a position on how to
address these products. The EC does not have a
position on how to regulate/deal with the variety
of diﬀerent NPM which is a big challenge, but in
any case it seems to be too early on having a
position on a possible REACH (EC, 2003)
approach for NPM. The existing regulations also
need to be examined and it needs to be determined
whether another type of legislation should address
nanoparticulate substances than those for bulk
substances.
Producers about regulations in occupational settings
The companies interviewed in this section can be
divided into the two categories young and estab-
lished companies, as described in the methodology
section.
1It is expected that the ﬁnal decision on REACH will be
reached by the European Parliament and Council in au-
tumn 2006 and that the operational requirements will be
applied from 2008 onwards. The new chemical legislation
will ,...reverse the burden of proof so that industry, both
producers and importers of substances, rather than the
public authorities, will have to assume greater responsibility
for providing the necessary information and taking eﬀective
risk management measures. (EC, 2005b).
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The young companies believe that for occupa-
tional settings, NPM are covered under current
regulations although the exposure levels might
need to be set diﬀerently for NPM than other
materials. These regulations should be speciﬁed for
the individual material and its form, but today and
at this stage in the development, it would be pre-
mature to introduce speciﬁc regulations especially
since the risks need to be scientiﬁcally demon-
strated. However, doing toxicology tests for each
individual material would be too expensive for the
industry. Issuing regulations demanding such
testing would fail as it would break the economy of
the industry. Therefore, regulators might consider
issuing guidelines rather than strict regulations and
disseminate information on toxicity to the indus-
try. At this stage in the development, the commit-
ment to the industrys Responsible Care2 program
would be enough.
The established companies treat NPM as
chemically ﬁne powder, therefore they see existing
chemical regulations as suﬃcient for these mate-
rials, but they may need to be more clearly speci-
ﬁed for this size range. Therefore, it is necessary to
discover speciﬁc knowledge of the toxicity of the
material and establish exposure limits based on the
right unit of measurement. Then, existing regula-
tions could be amended to regulate all areas from
laboratory and personal equipment against con-
cerns of work time and maximum work area
concentrations. It does not seem to be necessary to
establish new regulations for the implemented
occupation hygiene systems, but most of all, the
threshold levels have to be investigated, personal
monitoring methods are needed to improve safety
and materials handling at workplaces, and the
existing safety measures have to be adapted to
possible additional hazardous properties of the
NPM (Table 1).
Occupation Health Authorities about regulations
in occupational settings
All responding health authorities agreed there are
large uncertainties regarding the health risks and
hazards of NPM and knowledge gaps on the
exposure level as well as dose-response questions.
In addition, small particles are problematic espe-
cially considering the analogies of dust, asbestos
and ﬁbers, so more studies need to be done to ﬁll
the present data gaps, focusing on the kinetics,
inhalation, dermal exposure route, the body bur-
den that can be reached through the exposure
routes and the eﬀects on other organs. Today, for
example, it is only known that there will be an
eﬀect in the lungs, but the mechanisms needs to be
elaborated. The occupational regulatory body in
Germany is of the opinion that they must wait
until it is known which substances will be used in
the nanotechnologies and then assess these sub-
stances for risks. In the UK the risks from inha-
lation and dermal exposure to NPM are seen as
the same as would be considered for any new
chemical. One problem is that it is not possible to
determine which controls may be adequate before
toxicology is better understood. Currently, this is
to be done on a case-by-case basis. Some of the
new NPM are made to exhibit novel properties
that might be an issue for toxicity and could have a
diﬀerent toxicity value than with conventional
materials. This could for example be due to dif-
ferent dose kinetics as smaller particles dissolve
quicker or deposit diﬀerently in the lungs than
larger particles. It could also be that the NPM
have the same toxicity as bulk materials, but that
the way the NPM impacts the body is diﬀerent.
The severity of the risks of NPM is diﬃcult to
estimate as there are no epidemiological studies on
exposed humans and no exposure information.
The severity depends largely on how and where the
material is used. Occupational health authorities
state that they have to look at the containment of
the product and in which form it occurs, as NPM
in bulk powder form are likely to be more prob-
lematic than in liquid suspension. The occupa-
tional risk today might be quite low unless the
material has a toxicity which is extremely high and
containment is hard to achieve. The range of dif-
ferent NPM is signiﬁcant, consequently it is diﬃ-
cult to diﬀerentiate and rank what the concerns
might be for the diﬀerent types of NPM. However,
it is assumed that the smaller the particles are, the
greater are the hazards. It is reasonable to be most
concerned about getting data on the new novel
particles and ﬁbers and especially those with a
novel catalytic function or a novel binding func-
tion. Therefore, it is recommended to restrict
2Responsible Care – A voluntary program to achieve
improvements in environmental, health and safety perfor-
mance beyond levels required by the government (ICCA,
2005).
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exposure as much as technically possible as a
precautionary measure.
At the moment there is not enough known to
regulate the occupational settings and there is no
plan to regulate this area. In Switzerland they will
wait and see what is going on in this area and if it
is necessary, measures will be taken in cooperation
with producers. It is necessary to develop mea-
surement methods and limit values in air ﬁrst. If
the normal technical measures do not work for
NPM, special standards would be prescribed. In
Germany they foresee limit values to guide
industry and thereafter provide a speciﬁc standard.
In the UK they do not pereceive nanotechnology
as one subject, because it is many diﬀerent tech-
nologies, products and processes. In the UK, they
do not believe a special set of regulations will be
needed to cover nanotechnology, but rather an
amendment of existing ones as, for example,
including nano-ﬁbers in the deﬁnition of ﬁbers.
The risks of nanotechnology will probably be
covered in the day-to-day industrial routine in the
future, such as the risk of e.g., electric shocks is
covered today (Table 2).
Discussion
Comparing the stakeholder perceptions
The regulatory bodies and industry seem to be
aware that there might be potential risks of NPM
and concur it is not possible today to perform a
traditional risk assessment based on the current
knowledge level. They support that more research
should be done on diﬀerent types of NPM and that
these materials need to be assessed on a case by
case basis. Not only the EC but also the occupa-
tional authorities seem to give this area a low
priority as they have not seen any scientiﬁc
research that shows reasons for great concern.
However, if evidence demonstrates rationales for
concerns, the authorities will try to regulate the
area. However, at the moment there exists no plan
on how to do it. The authorities and industry seem
to foresee amending existing regulations as more
likely than creating new ones.
Whereas the occupational health regulatory
bodies in UK, Switzerland and Germany, are
awaiting scientiﬁc results before taking any
actions, there are to some degree diﬀerent
approaches on how to deal with this complex
problem. It seems the regulatory body in the UK is
taking a more active role by initiating some review
studies and preparing some guidelines for industry.
The regulatory body in Germany has recently
started to inform and involve themselves in the
issue, whereas the regulatory body in Switzerland
is more passive.
The NGO has taken on the role as an early
whistle blower, provoking debate around the
regulatory issue. It is also an important actor in
contextualizing the debate for the media
impacting the public opinion on NPM issues. It
seems important to recognize the function of the
NGO and utilize their positive attributes to
inﬂuence a safe and responsible development of
NPM.
Mindful the amounts of chemicals that are
untested but market available, it is reasonable to
Table 1. Summary of industry perception on regulations of occupational settings
Young Companies Established Companies
Risks need to be scientiﬁcally demonstrated. Existing regulations on ﬁne powder amended
for NPM.
NPM are covered under current regulation. Individual knowledge on substances needs
to be gained ﬁrst.
Regulations should be speciﬁed for the individual material
and its form.
Exposure levels should be established.
Exposure levels might need to be amended.
Too expensive to do toxicological tests on each material
for industry.
Guidelines may be better than regulations.
Authorities should disseminate information.
In the current stage of development, the voluntary
industry commitment to Responsible Care is suﬃcient.
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believe that it will also take many years before
there is a suﬃcient knowledge base for the regu-
latory bodies to perform the traditional risk
assessments of NPM and implement risk man-
agement actions. As seen from Table 3, both
industry and regulatory bodies are concurrent in
their views that regulations should only be initi-
ated after the scientiﬁc knowledge base indicates
clearly that NPM are hazardous. Furthermore, all
stakeholders seem to want a case-by-case evalua-
tion of the NPM. However, the researchers do not
yet understand the fundamentals behind the
properties of NPM. As such, achieving a suﬃcient
level of knowledge demands much more research
which we believe will take several years.
We also found in our research what appears to
be some confusion about the terminology regard-
ing NPM. The diﬀerent stakeholder groups inter-
viewed used diﬀerent terms such as chemicals,
ultraﬁne particles, nanoparticles, and nanomate-
rials. Therefore, a future task may be to develop a
common terminology for all stakeholders, which
would be especially important for discussing reg-
ulatory policy issues.
Implications for regulatory policy
In environmental settings, the gap of time between
cause and eﬀects is often much greater than the gap
between human exposure and impacts. This makes
it more diﬃcult to provide the suﬃcient amount of
scientiﬁc evidence that regulatory bodies normally
demands. Industry, as illustrated in Table 1,
believes that regulations should be imposed only
when suﬃcient scientiﬁc evidence exists that justi-
ﬁes the need. The voluntary measures taken by
industry themselves are seen by the industry as a
suﬃcient level of precautionary measures. Whether
the industry acknowledges the responsibility
beyond protecting their workers against occupa-
tional risks to other stages of the life cycle of their
products remains unknown. With the speed of
technological development and the widespread
foreseen market launching of NPM-based prod-
ucts, it may be insuﬃcient and unrealistic to leave
precautionary measures only to the industry.
How much research is undertaken by industry is
diﬃcult to estimate as the results remain normally
unpublished and hidden from the public sphere.
This practice was conﬁrmed by an industrial rep-
resentative in one of the interviews, blaming this
on competitive reasons. The authors are only
aware of a limited number of initiatives in Europe
where the industry is partnering and the public can
get insight into the results, such as the EU funded
project NanoSafe2 (Nanosafe, 2006). The limited
contributions from industry to the publicly avail-
able knowledge base would mean that it is public
research money that has to ﬁnance this funda-
mental research. Whether it is legitimate to have
public money ﬁnance and prove whether industrial
products are safe seems an important question to
Table 2. Summary of occupational health authorities perception
Uncertainties Research Focus Action
What will the exposure be? Kinetics of the particle/material. Wait until it is known which type
of substance will be used in
nanotechnologies and then do a
risk assessment.
Which substances will be used? Elaboration of the lung response. Case by case examination.
What is the dose-response? Dermal exposure route. Harmonize the test methods.
How will NPM contribute to the body
burden?
Eﬀects on secondary organs. Contained usage of NPM when
appropriate.
Will the novel characteristics of the new
NPM also be an issue for toxicology?
Epistemiological studies on humans.
NPM may have the same toxicity as bulk,
but will it impact the body in a
diﬀerent way?
Toxic properties of the particle/material.
What should be measured? (Mass/surface
area/volume)
Exposure data and methods
Will each NPM have its own characteristic? All particles with novel, catalytic
or binding properties (more
concerning)
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pose. Also, it could be argued that private stake-
holders should provide resources for establishing
the scientiﬁc evidence necessary that enables them
to reap future proﬁts in the market. The practice of
industry to refuse to share results of some of their
research may need to be challenged by regulatory
bodies as transparency in technological develop-
ment is fundamental for public trust and accep-
tance. The introduction of a disclosure practice
would without much doubt both boost the scien-
tiﬁc knowledge base and give all stakeholders a
better chance for a sound evaluation of whether
NPM pose risks to human health and the envi-
ronment. In the long term, industry may proﬁt
from it in terms of the potential for increased
consumer conﬁdence in their products. To make
this happen, changes related to risk assessment
practices and decision making processes may need
to take place both within regulatory bodies as well
as industry. By demanding industry demonstrate
their products are safe throughout the lifecycle,
consumers may have greater conﬁdence in the
safety of these products for human health and the
environment. Therefore, it may be time for
applying the precautionary principle as a tool for
boosting the scientiﬁc knowledge base and increase
transparency.
At the moment, there are few initiatives in
relation to regulatory policy in Europe. There are,
however, some international initiatives. For
example the International Council of Nanotech-
nology (ICON) has recently launched a research
project that will investigate and recommend best
practices for nanomaterials in industry (ICON,
2005). Establishing industry voluntary initiatives
and self-regulations are important ﬁrst steps to
improve the practices in industry. The challenge is
for the industry to follow up and continuously
improve these practices once they are established
and from a regulatory perspective to ensure that
these voluntary initiatives are suﬃcient to safe-
guard the human health and environment.
Another initiative is the global initiative of risk
governance for nanotechnology under develop-
ment by the Geneva based organisation IRGC,
where stakeholder participation is one of the cen-
tral elements (IRGC, 2004).
Closing remarks
Perceptions of regulations diﬀer among the
stakeholders. Although everybody seem to agree
that some sort of regulations should be in place,
there is disagreement on what type of regulations
that should be. The scientiﬁc uncertainty regard-
ing the risks of NPM makes the regulatory issue
complex and ambiguous. To decrease the scientiﬁc
uncertainty, more resources need to be committed
to scientiﬁc research on the risk potential of
NPM. However, the industry seems uncommitted
to provide resources for this research, thus the
burden may be on regulators to demonstrate
whether NPM are safe or could potentially be
dangerous. The assumption that tax-payers
money should be allocated for this type of
research may be unjustiﬁed as it is still greatly
unknown how these industrial products will ben-
eﬁt the public. Therefore, industry should con-
tribute to the scientiﬁc knowledge base.
Consequently, we recommend regulations that
ensure these contributions.
Table 3. Overview and comparison of the stakeholders perception




Need for Regulations Yes x x x x x
No




Point of time Evidence Oriented x x x
Proactive x x
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